Peptide News Digest

#Carl-June

2 stories

Industry · View digest

AACR 2026 Opening Plenary: Carl June on CAR-T Solid Tumor Progress, Regina Barzilay on AI, Charles Sawyers on Precision Oncology

The AACR 2026 Opening Plenary Session — 'Precision, Partnership, Purpose: Advancing Cancer Science to Save Lives Globally' — runs Sunday April 19, 9:30-11:30 a.m. PT. Cochaired by Paul Mischel (Stanford) and Alice Shaw (Dana-Farber), speakers include Carl June (Penn, armored CAR-T for solid tumors, glioblastoma), Georg Winter (AITHYRA), Regina Barzilay (MIT), and Charles Sawyers (MSK). The program sets the tone for a meeting in which peptide-based modalities, ADCs, and PDCs are taking center stage.

Industry · View digest

Verismo Therapeutics Secures $28M From HLB Innovation Ahead of AACR 2026 Late-Breaking KIR-CAR Clinical Debut

Verismo Therapeutics announced a $28 million investment from HLB Innovation to accelerate clinical development of its KIR-CAR platform, timed to the company's first-ever presentation of SynKIR-110 Phase 1 (STAR-101) multi-chain KIR-CAR clinical data in the AACR 2026 Late-Breaking Clinical Trials plenary (April 20). Verismo is a Penn/Carl June spinout using a modified NK-cell-derived receptor and DAP12 pairing to improve T-cell persistence.